SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

Syncona said the performance was mostly driven by a decline in Autolus Therapeutics PLC share price and a weaker US dollar, and was partially offset by valuation uplifts from private portfolio company ...

These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation ...

In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

VIPER-101 leverages the company's proprietary Senza5 TM platform technology, which enhances T cell effector function by ...

Scientists at Vilnius University have developed a novel gene silencing method using a type IV-A CRISPR system that silences ...

Researchers at UC San Diego have examined the critical role of goblet cells in gut immunity and health. GCs create a mucus ...